Suppr超能文献

一项针对医院的基于电子处方的复杂抗菌药物管理(ePAMS+)干预措施,融合技术和行为要素:一项可行性试验方案

A complex ePrescribing-based Anti-Microbial Stewardship (ePAMS+) intervention for hospitals combining technological and behavioural components: protocol for a feasibility trial.

作者信息

Weir Christopher J, Adamestam Imad, Sharp Rona, Ennis Holly, Heed Andrew, Williams Robin, Cresswell Kathrin, Dogar Omara, Pontefract Sarah, Coleman Jamie, Lilford Richard, Watson Neil, Slee Ann, Chuter Antony, Beggs Jillian, Slight Sarah, Mason James, Yardley Lucy, Sheikh Aziz

机构信息

Edinburgh Clinical Trials Unit, Usher Institute, University of Edinburgh, Edinburgh, UK.

Usher Institute, University of Edinburgh, Edinburgh, UK.

出版信息

Pilot Feasibility Stud. 2023 Jan 28;9(1):18. doi: 10.1186/s40814-022-01230-w.

Abstract

BACKGROUND

Antimicrobial resistance is a leading global public health threat, with inappropriate use of antimicrobials in healthcare contributing to its development. Given this urgent need, we developed a complex ePrescribing-based Anti-Microbial Stewardship intervention (ePAMS+).

METHODS

ePAMS+ includes educational and organisational behavioural elements, plus guideline-based clinical decision support to aid optimal antimicrobial use in hospital inpatients. ePAMS+ particularly focuses on prompt initiation of antimicrobials, followed by early review once test results are available to facilitate informed decision-making on stopping or switching where appropriate. A mixed-methods feasibility trial of ePAMS+ will take place in two NHS acute hospital care organisations. Qualitative staff interviews and observation of practice will respectively gather staff views on the technical component of ePAMS+ and information on their use of ePAMS+ in routine work. Focus groups will elicit staff and patient views on ePAMS+; one-to-one interviews will discuss antimicrobial stewardship with staff and will record patient experiences of receiving antibiotics and their thoughts on inappropriate prescribing. Qualitative data will be analysed thematically. Fidelity Index development will enable enactment of ePAMS+ to be measured objectively in a subsequent trial assessing the effectiveness of ePAMS+. Quantitative data collection will determine the feasibility of extracting data and deriving key summaries of antimicrobial prescribing; we will quantify variability in the primary outcome, number of antibiotic defined daily doses, to inform the future larger-scale trial design.

DISCUSSION

This trial is essential to determine the feasibility of implementing the ePAMS+ intervention and measuring relevant outcomes, prior to evaluating its clinical and cost-effectiveness in a full scale hybrid cluster-randomised stepped-wedge clinical trial. Findings will be shared with study sites and with qualitative research participants and will be published in peer-reviewed journals and presented at academic conferences.

TRIAL REGISTRATION

The qualitative and Fidelity Index research were approved by the Health and Research Authority and the North of Scotland Research Ethics Service (ref: 19/NS/0174). The feasibility trial and quantitative analysis (protocol v1.0, 15 December 2021) were approved by the London South East Research Ethics Committee (ref: 22/LO/0204) and registered with ISRCTN ( ISRCTN 13429325 ) on 24 March 2022.

摘要

背景

抗菌药物耐药性是全球主要的公共卫生威胁之一,医疗保健中抗菌药物的不当使用促使了其发展。鉴于这一迫切需求,我们开发了一种基于电子处方的复杂抗菌药物管理干预措施(ePAMS+)。

方法

ePAMS+包括教育和组织行为要素,以及基于指南的临床决策支持,以帮助优化医院住院患者的抗菌药物使用。ePAMS+特别关注抗菌药物的及时启用,然后在获得检测结果后尽早进行复查,以便在适当情况下就是否停药或换药做出明智决策。将在两个国民保健服务(NHS)急性医院护理机构中开展一项ePAMS+的混合方法可行性试验。对工作人员进行定性访谈以及观察实践情况,将分别收集工作人员对ePAMS+技术组件的看法以及他们在日常工作中使用ePAMS+的信息。焦点小组将征集工作人员和患者对ePAMS+的看法;一对一访谈将与工作人员讨论抗菌药物管理,并记录患者接受抗生素治疗的经历以及他们对不当处方的看法。将对定性数据进行主题分析。制定保真度指数将能够在后续评估ePAMS+有效性的试验中客观衡量ePAMS+的实施情况。定量数据收集将确定提取数据和得出抗菌药物处方关键摘要的可行性;我们将对主要结果(抗生素限定日剂量数)的变异性进行量化,为未来更大规模的试验设计提供信息。

讨论

在全面的混合整群随机阶梯楔形临床试验中评估其临床和成本效益之前,该试验对于确定实施ePAMS+干预措施和衡量相关结果的可行性至关重要。研究结果将与研究地点以及定性研究参与者分享,并将发表在同行评审期刊上,并在学术会议上展示。

试验注册

定性研究和保真度指数研究已获得健康与研究管理局以及苏格兰北部研究伦理服务委员会的批准(参考编号:19/NS/0174)。可行性试验和定量分析(方案版本1.0,2021年12月15日)已获得伦敦东南部研究伦理委员会的批准(参考编号:22/LO/0204),并于2022年3月24日在国际标准随机对照试验编号注册库(ISRCTN)注册(ISRCTN 13429325)。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fb7/9883944/7a12963ca875/40814_2022_1230_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验